Yinjia Biosciences will provide Porton Advanced with high-quality core protein raw materials and testing reagent products for quality control and evaluation systems.
This sBLA submission is supported by clinical, pre-clinical, and manufacturing data demonstrating the safety, tolerability, and immunogenicity of the bivalent vaccine.
Submissions based on favorable MagnetisMM-3 trial results in patients with relapsed or refractory multiple myeloma
Projected ~US$100 million cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months
More than 5 lakh patients availed the benefit of queue-less OPD registration using this service
Clinical studies are expected to start in Q2 2023.
Ghostine has served as CEO of Geneva-based Firmenich, the world's largest privately owned perfume and taste company, since 2014.
Alkem has submitted a detailed corrective and preventive action (CAPA) plan to the regulator within the stipulated timelines.
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial
Ayurveda is one of the most advanced sciences of its times
Subscribe To Our Newsletter & Stay Updated
